Skip to main content
. Author manuscript; available in PMC: 2016 Jul 15.
Published in final edited form as: Cell Rep. 2016 Jun 23;16(2):457–471. doi: 10.1016/j.celrep.2016.05.087

Figure 4. EGFR regulates TET1 expression via the transcription factor C/EBPα (See also Figures S3 and S4).

Figure 4

(A) The indicated lung cancer cell lines were treated with afatinib (0.1 μM) for 48 h, and the mRNA and protein expression levels of the transcription factor C/EBPα were analyzed via RT-qPCR (Left) or immunoblot analysis (Right), respectively. (B) The HCC827/Del cell line expressing C/EBPα or non-specific (NS) shRNAs was treated with afatinib (0.1 μM) for 48 h, and analyzed for TET1 mRNA expression or TET1 protein expression via RT-qPCR (Left) or immunoblot analysis (Right), respectively. (C) The HCC827/Del cell line was treated with afatinib (0.1 μM) for 48 h, and the occupancy of C/EBPα on the TET1 promoter was analyzed via ChIP. The relative enrichment of C/EBPα in afatinib-treated cells was compared with that of an IgG control. is shown at two predicted C/EBPα. (D and E) HCC827/Del cells expressing TET1 or NS shRNAs were treated with afatinib (0.1 μM) for 48 h, and analyzed for TET1 expression and TSG mRNA and protein levels via RT-qPCR (D) and immunoblot analysis (E), respectively. (F) HCC827/Del cells were treated with afatinib (0.1 μM) for 48 h, and analyzed for TET1 occupancy on the promoters of the indicated TSGs via ChIP. *p < 0.05 and **p < 0.005.